Dimension Therapeutics, which is developing novel, liver-directed gene therapies for rare genetic disorders, filed on Monday with the SEC to raise up to $115 million in an initial public offering.
Dimension Therapeutics licenses its AAV vector gene delivery technology from REGENXBIO (RGNX), which is on the IPO calendar to raise $100 million this week.
Help employers find you! Check out all the jobs and post your resume.
Dimension Therapeutics licenses its AAV vector gene delivery technology from REGENXBIO (RGNX), which is on the IPO calendar to raise $100 million this week.
Help employers find you! Check out all the jobs and post your resume.
